Upper Limb Spasticity Post-Stroke
Conditions
Brief summary
This study aims to estimate the costs of botulinum toxin A utilization in standard practice for the treatment of upper limb spasticity post-stroke in Portugal. It will consider the three most used locally available brands of botulinum toxin A which show similar efficacy and safety profiles thus making it relevant to understand if choosing between one or another brand can depend directly on economic factors. The study will estimate direct and indirect drug-associated costs as determinant variables for the price of each drug and the standard drug dose used in clinical practice.
Detailed description
A comparison will be performed between direct costs associated with each therapeutic strategy and cost analysis assuming that quality of life values may be different between patients treated with each treatment.
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with post-stroke upper limb spasticity * Patients currently being treated with Dysport®, Botox® or Xeomin® * Patients stabilized from a therapeutic point of view - with no switches of treatment in at least the 2 last administrations * Patients who gave their written informed consent to participate.
Exclusion criteria
* Not applicable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimate the cost of botulinum toxin utilization | 12 months | Direct resource utilization and costs of upper limb spasticity patients treated with BoNT-As, by product |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of work days missed due to spasticity | 12 months | Assessment of Absenteeism /loss of productivity |
| Carer time needed for patient assistance | 12 months | — |
Countries
Portugal
Outcome results
None listed